A relatively easy way to encourage your Black patients with MS to participate in clinical research is to introduce them to ...

Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Pipeline Report ...

Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway ...

The Maryland-based biotech announced the clinical hold last month after a participant ... Novavax said on Monday it had ...

Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune ...

Researchers explain how a drug that helps patients with neurological issues walk may also provide a surprising boost for the ...

In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational ... and possibly viral infections. Common symptoms of multiple sclerosis include fatigue, ...

Multiple sclerosis (MS) is a neurodegenerative disease that causes demyelination of the CNS. MS can cause a wide variety of neuro-ophthalmic manifestations and is also associated in some cases ...

A newly awarded grant from the ALS Association will support Asha Therapeutics' work to advance ASHA-624 into a first-in-human ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control (CDSCO) has granted ...

today announces it will start a phase I/II clinical study in Australia for patients with Amyotrophic Lateral Sclerosis (ALS). The launch of this ALS study follows the recent approval by the Australian ...

Through research in the Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic is leading scientific advances in multiple sclerosis treatment.